Scottish Widows Investment Partnership
VC Fund
Edinburgh, United Kingdom
Scottish Widows Investment Partnership is a VC fund in Edinburgh focused on Therapeutics and Biotechnology. Scottish Widows Investment Partnership – SWIP – is one of the largest asset management companies in Europe. Their teams are recognised as high fliers within the industry. Their performance is based on their skills, backed by thorough research, and the ability to uncover and capitalise on opportunities as soon as they arise.They invest across allasset classes, including equities, property, bonds and cash. They also offer specialist expertise in multi-manager and multi-asset solutions.Their goal: to provide superior risk-adjusted returns and quality service for their clients, which include individuals, pension funds, charities and financial institutions from around the world.Whatever your investment requirements, their teams have the innovation, drive and skill to deliver investment solutions that perform.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Scottish Widows Investment Partnership invests in
Stages Scottish Widows Investment Partnership invests in
Countries Scottish Widows Investment Partnership invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew November
|
|||
Francis Ghiloni
|
|||
Sean Phayre
|
|||
Tony Owens
|
|||
William Low
|
Investment Focus
Industry
- Therapeutics 2 (40%)
- Biotechnology 2 (40%)
- Health Care 1 (20%)
- Pharmaceutical 1 (20%)
Stage
- Series D 2 (40%)
- Series C 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrew November
Director of Investment Propositions
|
Director of Investment Propositions | Total investments: 0 | Find email | |
|
Francis Ghiloni
Director of Distribution & Client Management
|
Director of Distribution & Client Management | Total investments: 0 | Find email | |
|
Sean Phayre
Head of Quantitative Investments
|
Head of Quantitative Investments | Total investments: 0 | Find email | |
|
Tony Owens
Director of Operations, Strategy & Finance
|
Director of Operations, Strategy & Finance | Total investments: 0 | Find email | |
|
William Low
Director
|
Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Zenobe Energy
|
Zenobe Energy ( formerly known as Battery Energy Storage Solutions Limited) is the largest independent owner and operator of battery storage in the UK. We transform the way grid operators and businesses use power to reduce costs, improve reliability and benefit the environment. | $520.6M / Debt Financing / May 29, 2024 | |
Cara Therapeutics
|
Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patentedcompound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology. | $15M / Series D / Jul 21, 2010 | |
|
Cara Therapeutics
|
Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patentedcompound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology. | $24M / Series C / Nov 28, 2006 | |
ARYx Therapeutics
|
ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease. | $30.4M / Series E / Feb 10, 2006 | |
|
ARYx Therapeutics
|
ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease. | $55M / Series D / Jun 01, 2004 |
Co-Investors
Ascent Biomedical Ventures
3 deals together
Alta Partners
2 deals together
Merlin Biomed
2 deals together
Montreux Equity Partners
2 deals together
MPM Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Scottish Widows Investment Partnership invest in?
Scottish Widows Investment Partnership invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Series D and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Scottish Widows Investment Partnership?
Public channels for Scottish Widows Investment Partnership include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Scottish Widows Investment Partnership?
The team at Scottish Widows Investment Partnership includes Andrew November (Director of Investment Propositions), Francis Ghiloni (Director of Distribution & Client Management) and Sean Phayre (Head of Quantitative Investments). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
